No guidelines matched your search.
Try a shorter keyword like "MASLD", "fibrosis", or "Baveno".
MASLD / MASH β Assessment & Nomenclature
Guidelines covering the diagnosis, screening, and classification of metabolic dysfunctionβassociated steatotic liver disease (formerly NAFLD/NASH).
Why NAFLD was renamed to MASLD and NASH to MASH, how MASLD is defined using cardiometabolic risk criteria, the five-category SLD classification, and what changed (and didn't) for your diagnosis.
Who should be screened for fatty liver fibrosis, the FIB-4 β FibroScan/ELF two-step algorithm, what lifestyle changes help, and which medications may benefit patients β the AASLD's comprehensive practice guidance.
Cirrhosis & Portal Hypertension
Guidelines on diagnosing and managing cirrhosis and its associated complications such as clinically significant portal hypertension, varices, and preventing variceal bleeding.
FibroScan thresholds for ruling in/out portal hypertension, the Rule of 5, when you can skip endoscopy, how beta-blockers help, variceal bleeding management, and the concept of recompensation.
Non-invasive CSPH diagnosis, who should receive beta-blockers or band ligation, how acute variceal bleeding is managed with endoscopy and TIPS, and preventing rebleeding β the AASLD's updated practice guidance.
EASL 2023 guidelines on liver disease in pregnancy: ICP thresholds, HELLP, AFLP, viral hepatitis, and safe medication guidance explained in plain language.
Nutrition & Treatment
This section contains nutrition guidance by EASL and AASLD for chronic liver disease patientys. There are also drug-specific guidance for FDA-approved (accelerated) therapies targeting MASH with fibrosis: who qualifies, monitoring protocols, and trial results.
Plain-language summary of EASL's 2019 clinical guidelines on nutrition in cirrhosis. Covers protein targets, sarcopenia, obesity, vitamin D, bone disease, HE diet, and transplant nutrition.
AASLD 2021 guidance on malnutrition, frailty, and sarcopenia in cirrhosis: assessment tools, nutrition targets, exercise recommendations, and monitoring schedules.
Who qualifies for resmetirom, what non-invasive tests you need, how doctors monitor treatment response, drug interactions to watch for, and side effects β based on the MAESTRO-NASH trial results.
Who qualifies for semaglutide, the non-invasive testing pathway, how doctors monitor your response, and what side effects to expect β based on the ESSENCE trial and the AASLD's latest practice guidance.
More Guidelines Coming Soon
We're expanding this library with additional society guidelines and consensus statements. Future additions will include: